Comparative analysis on the price and efficacy of sotoracib (AMG 510) generic drugs and original drugs

Sotorasib (Sotorasib, AMG 510) is a KRAS G12C inhibitor and the world's first approved oral small molecule targeted drug targeting the KRAS G12C mutation. KRAS mutations have long been considered an "undruggable" target, and the advent of sotorasiib has broken through the technical bottleneck in this field and is of great significance to patients with tumors related to KRAS G12C mutations such as advanced non-small cell lung cancer. Clinical trial results show that sotorasiib can significantly improve the objective response rate and progression-free survival of patients with KRAS G12C mutated advanced lung cancer, so it has attracted much attention.

Currently, sotoracib is not available in mainland China, and domestic patients cannot purchase it directly in hospital pharmacies. In overseas markets, the drug is produced by the original manufacturer Amgen (Amgen). The main sales versions are the European version and the Hong Kong version. The price is generally in the range of "tens of thousands of yuan", which imposes a heavy financial burden. Especially for patients with advanced tumors who require long-term treatment, the cost of continuous treatment may become a huge economic pressure, which is also one of the main obstacles to clinical application in China.

In comparison, generic versions of sotorasibu have been launched in some foreign regions, with the Lao version being the most well-known. At present, the price of generic drugs of sotorasibu produced by Lao Lucius (Lucius) and Lao Bears (Bears) has been significantly reduced. 120mg*56 tablets are sold for only more than 1,000 yuan, which is significantly lower than the price of the original drug. More importantly, generic drugs are consistent in active ingredients and dosage with original drugs, and can achieve similar clinical efficacy, providing a feasible treatment path for many patients with greater financial pressure.

From the perspective of efficacy, there is no essential difference in active ingredients between compliantly produced generic drugs and original drugs, and their pharmacological mechanisms of action are the same. Some patients report that after actually using generic drugs, the efficacy is similar to that of the original drug. However, it should be noted that the quality standards of generic drugs may differ depending on the country of production and the qualifications of the company. Therefore, when choosing generic drugs, patients should try to purchase them through formal channels, pay attention to the manufacturer's reputation and drug approval documents, and avoid purchasing substandard or counterfeit products. Taken together, for patients with limited financial conditions or long-term medication, the more affordable Laotian generic drugs are a realistic alternative, while those with financial conditions can choose original drugs to obtain more complete drug tracking and medication protection.

Reference materials:https://www.drugs.com/